Market closed
Entrada Therapeutics/$TRDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Ticker
$TRDA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
183
Website
TRDA Metrics
BasicAdvanced
$290M
4.84
$1.68
-0.17
-
Price and volume
Market cap
$290M
Beta
-0.17
52-week high
$21.19
52-week low
$7.10
Average daily volume
140K
Financial strength
Current ratio
11.145
Quick ratio
10.777
Long term debt to equity
12.048
Total debt to equity
13.812
Management effectiveness
Return on assets (TTM)
5.90%
Return on equity (TTM)
19.56%
Valuation
Price to earnings (TTM)
4.839
Price to revenue (TTM)
1.439
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-6.783
Growth
Revenue change (TTM)
63.38%
Earnings per share change (TTM)
-930.59%
3-year earnings per share growth (CAGR)
-40.96%
What the Analysts think about TRDA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
TRDA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TRDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TRDA News
AllArticlesVideos
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
GlobeNewsWire·4 weeks ago
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·2 months ago
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $290M as of April 20, 2025.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 4.84 as of April 20, 2025.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of -0.17. This means that it has an inverse relation to market volatility.